Starting antiviral treatment as late as 14 days after infection with SARS-CoV-2 may still be beneficial in hosts with compromised immune systems, who are at greatest risk of developing severe COVID-19, according to researchers in the Center for Translational Antiviral Research at Georgia State University’s Institute for Biomedical Sciences.
Delayed antiviral treatment still beneficial for immunocompromised COVID-19 patients
- Post author:
- Post published:September 3, 2024
- Post category:uncategorized